←Back to Expert Scholars
Translational Medicine / 转化医学Lung Cancer Immunotherapy
Julie Brahmer
MD
🏢Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins🌐USA
Director, Thoracic Oncology and Professor of Oncology
100
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Julie Brahmer has led pivotal trials of nivolumab and pembrolizumab in non-small cell lung cancer and contributed to establishing PD-L1 as a predictive biomarker. She leads the thoracic oncology program at Johns Hopkins.
Share:
🧪Research Fields 研究领域
NSCLC immunotherapy
PD-1 trials
KEYNOTE-024
adjuvant immunotherapy
biomarker testing
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Julie Brahmer 的研究动态
Follow Julie Brahmer's research updates
留下邮箱，当我们发布与 Julie Brahmer（Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment